Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
Humam Kadara(The University of Texas MD Anderson Cancer Center), Roy S. Herbst(The University of Texas MD Anderson Cancer Center), Thomas J. Lynch(Yale Cancer Center), Edward Kaftan(University of Connecticut), Carmen Behrens, Jaime Rodriguez‐Canales(The University of Texas MD Anderson Cancer Center), Don L. Gibbons(The University of Texas MD Anderson Cancer Center), Chi-Wan Chow(The University of Texas MD Anderson Cancer Center), David L. Rimm(Yale University), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Stephen G. Gaffney(Yale University), J. Lee(Indiana University Health), Edwin R. Parra(The University of Texas MD Anderson Cancer Center), Richard P. Lifton(Yale University), John V. Heymach(The University of Texas MD Anderson Cancer Center), J. Zhang(Indiana University Health), Joseph Schlessinger(Yale University), Stephen G. Swisher(The University of Texas MD Anderson Cancer Center), Junya Fujimoto(The University of Texas MD Anderson Cancer Center), Jeffrey P. Townsend(Yale University), Yongjin Yoo(California Institute for Regenerative Medicine), Neda Kalhor(The University of Texas MD Anderson Cancer Center), César A. Moran(The University of Texas MD Anderson Cancer Center), Zhenghong Zhao(Yale University), Murim Choi(Seoul National University)
Cited by 209
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k